Establishment of an RPA-CRISPR/Cas12a combined diagnostic system for Pneumocystis jirovecii pneumonia
PLOS Neglected Tropical Diseases · 2025
DOI: 10.1371/journal.pntd.0012922 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Yun Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Pneumocystis carinii, Pneumonia, Pneumocystis, CRISPR-Cas Systems, Nucleic Acid Amplification Techniques. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pneumocystis jirovecii causes severe pneumonia in immunocompromised individuals, leading to high mortality and an economic burden. There is a need for early detection methods suitable for low-resource settings and rapid point-of-care diagnostics. This study developed a detection method using Recombinase Polymerase Amplification (RPA) followed by CRISPR/Cas12a with fluorescence detection. The RPA primers and CRISPR-derived RNAs (crRNAs) were specifically designed to target the mitochondrial small subunit rRNA (mtSSU rRNA) gene of P. jirovecii . A total of 83 clinical samples were tested using this method, including 39 confirmed and 44 suspected cases of P. jirovecii infection. The combination of crRNA5 and crRNA6 demonstrated higher sensitivity compared to the current real-time PCR detection method, with a limit of detection (LOD) of 1 copy per reaction and showed no cross-reactions with other respiratory pathogens. The concordance of this method was validated with both infected and non-infected patients. In conclusion, the method developed in this study potentially provides a highly sensitive and rapid tool suitable for the early and on-site detection of P. jirovecii pneumonia. Furthermore, this method holds potential applications for the detection of other human pathogens, representing a significant advancement in diagnostic capabilities for low-resource settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Warwick Medical School, Warwick University, Coventry, United Kingdom.
ORCID-Profile: Guowei Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, Y., Shao, Y., Li, W., Yu, Y., Rao, X., Li, J., Waterfield, N. R., & Yang, G. (2025). Establishment of an RPA-CRISPR/Cas12a combined diagnostic system for Pneumocystis jirovecii pneumonia. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012922
Vancouver
Wu Y, Shao Y, Li W, Yu Y, Rao X, Li J, et al. Establishment of an RPA-CRISPR/Cas12a combined diagnostic system for Pneumocystis jirovecii pneumonia. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0012922
BibTeX
@article{Wu2025,
author = {Wu, Yun and Shao, Yuhan and Li, Wei and Yu, Ying and Rao, Xia and Li, Jingyi and Waterfield, Nicholas R and Yang, Guowei},
title = {Establishment of an RPA-CRISPR/Cas12a combined diagnostic system for Pneumocystis jirovecii pneumonia},
journal = {PLOS Neglected Tropical Diseases},
year = {2025},
doi = {10.1371/journal.pntd.0012922}
}
EUVIMED